The Effect of Lanthanum Carbonate on Fibroblast Growth Factor 23 ( FGF23) in Chronic Kidney Disease
Status:
Unknown status
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
The aim of the study is to assess the effects of the drug lanthanum carbonate (a phosphorus
binder drug) on c-terminal and on FGF23 levels in patients with Chronic Kidney Disease (CKD).
Targeting FGF23 measurement in CKD patients may impact both the progression of kidney disease
and patient mortality.
Phase:
N/A
Details
Lead Sponsor:
NorthShore University HealthSystem NorthShore University HealthSystem Research Institute